The UDIC will start a new clinical trial that evaluates the subcutaneous administration of levodopa, using a continuous perfusion pump, to treat motor fluctuations in advanced Parkinson’s isease. It will compare with standard Levodopa in a double-blind study. Up to now this has not been possible due to high volume required. This “ultra concentrated” levodopa allows its subcutaneous administration, for an adequate control of the motor blockages that cause so much suffering to the patients. It is intended to improve their quality of life. In January 2020 the investigators meeting will be held in Barcelona.